Pharus Diagnostics Company Profile

Background

Pharus Diagnostics (PharusDx) is an innovative healthcare company specializing in non-invasive diagnostic tests for early cancer detection. Headquartered in Hsinchu, Taiwan, with offices in Hong Kong and Los Angeles, PharusDx aims to become the premier provider of affordable and widely accessible liquid biopsy tests. The company's mission is to detect cancer early, thereby improving patient outcomes and reducing the physical, emotional, and financial burdens associated with late-stage diagnoses.

Key Strategic Focus

PharusDx focuses on developing and commercializing liquid biopsy tests that utilize microRNA (miRNA) biomarkers and machine learning algorithms to detect multiple types of cancer at early stages. Their flagship product, OncoSweep™, is designed for Multi-Cancer Early Detection (MCED) and single-cancer screenings, offering a non-invasive, cost-effective, and easily repeatable screening option. The company targets individuals at elevated risk for cancers such as pancreatic ductal adenocarcinoma (PDAC), aiming to integrate these tests into existing health screening protocols.

Financials and Funding

PharusDx is backed by prominent investors, including CK Life Sciences, CK Hutchison, and LCY Group. In July 2022, CK Life Sciences and CK Hutchison announced a major investment in PharusDx, underscoring confidence in the company's technology and strategic direction.

Pipeline Development

PharusDx's primary product pipeline includes:

• OncoSweep™ Multi-Cancer Early Detection (MCED) Test: A liquid biopsy test capable of detecting multiple cancers through a simple blood draw. Preliminary data presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2020 demonstrated 86.5% overall accuracy, with 91.4% sensitivity and 85.0% specificity in detecting multiple cancers.

• OncoSweep™ Pancreas Spotlight: A Laboratory Developed Test (LDT) for early detection of PDAC, validated in December 2024. This test analyzes levels of miRNA and CA19-9 biomarkers using next-generation sequencing and proprietary machine learning algorithms.

Technological Platform and Innovation

PharusDx's technological platform is distinguished by:

• Proprietary miRNA Biomarkers: Licensed exclusively from City of Hope, these biomarkers enhance the sensitivity and specificity of cancer detection tests.

• Advanced Machine Learning Algorithms: Employed to analyze complex biomarker data, improving the accuracy of early cancer detection.

• Non-Invasive Liquid Biopsy Technology: Facilitates early detection through simple blood tests, making screening more accessible and less burdensome for patients.

Leadership Team

• Philip Huang, Chief Executive Officer: Appointed in October 2022, Mr. Huang brings nearly 20 years of leadership experience, including roles as Vice President of Roche Diagnostics' Asia Pacific Partnering Hub and Vice President of Global Business Development for EKF Diagnostics. He holds degrees in Chemical Engineering from MIT and Stanford, and an MBA from INSEAD.

• Bowei Lee, Chairman: Also Chairman of LCY Group, Mr. Lee plays a pivotal role in guiding PharusDx's strategic direction and securing key investments.

• Chester Chang, Director of Data Science: Leads the data science initiatives, focusing on the development and implementation of machine learning algorithms for diagnostic tests.

• Yen Jung Lu, Director of Product Development: Oversees the development and refinement of PharusDx's diagnostic products.

• Jin Huang, Head of Finance, Human Resources, and Administration: Manages the company's financial operations and administrative functions.

• Scott Taylor, Head of Commercial: Responsible for commercial strategies and market expansion efforts.

Leadership Changes

In October 2022, Philip Huang was appointed as Chief Executive Officer, succeeding the previous leadership. His extensive experience in diagnostics and business development positions him to lead PharusDx's growth and innovation initiatives.

Competitor Profile

Market Insights and Dynamics

The liquid biopsy market is experiencing significant growth, driven by the increasing demand for non-invasive cancer diagnostics and the rising prevalence of cancer worldwide. Early detection technologies are becoming a focal point for improving patient outcomes and reducing healthcare costs.

Competitor Analysis

Key competitors in the liquid biopsy space include:

• GRAIL: Focuses on multi-cancer early detection tests using cfDNA analysis and machine learning.

• Guardant Health: Offers comprehensive genomic profiling tests for advanced cancer patients and is expanding into early detection.

• Exact Sciences: Known for its colorectal cancer screening test, Cologuard, and developing liquid biopsy tests for multiple cancers.

• Freenome: Utilizes multiomics and machine learning to detect cancer early through blood tests.

Strategic Collaborations and Partnerships

PharusDx has established significant collaborations to enhance its technological capabilities:

• City of Hope: In February 2024, PharusDx entered into a global exclusive license agreement with City of Hope for proprietary miRNA biomarkers to be used in early screening of individuals at risk for PDAC.

• PacificDx: Partnered to develop and validate the OncoSweep™ Pancreas Spotlight LDT, leveraging PacificDx's CLIA-accredited laboratory facilities.

Operational Insights

PharusDx differentiates itself through:

• Proprietary Biomarker Technology: Exclusive access to City of Hope's miRNA biomarkers enhances test accuracy.

• Advanced Machine Learning Integration: Utilization of sophisticated algorithms improves diagnostic precision.

• Non-Invasive Testing: Liquid biopsy approach offers a patient-friendly alternative to traditional biopsies.

• Strategic Partnerships: Collaborations with leading research institutions and investors bolster credibility and resource access.

Strategic Opportunities and Future Directions

PharusDx is poised to:

• Expand Product Portfolio: Develop additional single-cancer and multi-cancer detection tests.

• Enter New Markets: Leverage existing partnerships to penetrate global markets, particularly in regions with high cancer prevalence.

• Enhance Technological Capabilities: Invest in research and development to refine machine learning algorithms and biomarker discovery.

• Strengthen Regulatory Compliance: Pursue necessary approvals to ensure widespread adoption of diagnostic tests.

Contact Information

For more information, visit PharusDx's official website.

Connect with PharusDx on LinkedIn.